Regulatory Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings Pharmaceutical TechnologyThe EMA's CHMP has stated its positive opinions on three drugs for autoimmune, muscle wasting and rare genetic diseases.RegulatoryRead full story pharminent April 24, 2026 (Last updated: April 24, 2026) Pharmaceutical Technology The EMA’s CHMP has stated its positive opinions on three drugs for autoimmune, muscle wasting and rare genetic diseases. RegulatoryRead full story Post navigation Previous: Daiichi Sankyo shares slip after delaying annual earnings reportNext: Gene therapy leaders aim to help more Baby KJs with novel regulatory models Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
